US FDA’s co-crystal final guidance to reduce cGMP burden

By Flora Southey

- Last updated on GMT

GettyImages/nikkytok
GettyImages/nikkytok

Related tags New drug application Food and drug administration

In response to stakeholder feedback, the US FDA has issued a final guidance detailing changes to the regulatory classification of co-crystals, from intermediate to API.

The US Food and Drug Administration (FDA) released the Regulatory classification of pharmaceutical co-crystals guidance​ this month, following its introduction in April 2013, and a revised draft​ in August 2016.

In the final guidance, the Agency advises new drug application (NDA) and abbreviated new drug application (ANDA) applicants that a co-crystal API meeting the guidance criteria will no longer be considered a drug product intermediate, but an API.

Pharma co-crystals

“In other words, the co-crystal form is considered in the same way as would any other morphic form of the API such as a polymorph, solvate or hydrate,” ​said the FDA.

Pharmaceutical co-crystals are composed of two or more different molecules, typically an active pharmaceutical ingredient (API) and an excipient.

In theory, the non-API component of a co-crystal can be modified to enhance drug process-ability, stability or bioavailability.

According to the FDA, “Pharmaceutical co-crystals have provided opportunities for engineering solid-state forms beyond conventional solid-state forms of an API, such as salts and polymorphs.

“Another advantage of co-crystals is that they generate a diverse array of solid-state forms for APIs that lack ionisable functional groups, which is a prerequisite for salt formation.”

Stakeholder feedback

The reclassification responds to stakeholder feedback, requesting the Agency clarify the appropriate classification of co-crystals and the regulatory consequences of such classifications.

In August, 2016 in-PharmaTechnologist reported​ drugmakers were reluctant to work with pharmaceutical co-crystals due to their classification as ‘intermediates’ – which require stricter manufacturing practices in the drug making process than solvates.

“In a commercial setting, co-crystals are typically manufactured in drug substance facilities. However, when classified as a drug product intermediate, additional current good manufacturing practice requirements (cGMPs) apply to co-crystals,” ​said the FDA at the time.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...